3D-Printed Microcubes for Catalase Drug Delivery.
Journal
ACS omega
ISSN: 2470-1343
Titre abrégé: ACS Omega
Pays: United States
ID NLM: 101691658
Informations de publication
Date de publication:
01 Aug 2023
01 Aug 2023
Historique:
received:
07
02
2023
accepted:
10
05
2023
medline:
7
8
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
Oxidative stress, i.e., excessive production of reactive oxygen species (ROS), plays an important role in the pathogenesis of inflammatory diseases such as cardiovascular diseases, cancer, and neurodegenerative diseases. Catalase, an antioxidant enzyme, has great therapeutic potential; however, its efficacy is limited by its delivery to target cells or tissues. In order to achieve efficient delivery, consistent drug distribution, and drug activity, small and uniformly sized drug delivery vehicles are needed. Here, three-dimensional (3D) microcubes were printed by Nanoscribe Photonic Professional GT2, a high-resolution 3D printer, and the characteristics of 3D-printed microcubes as drug delivery vehicles for the delivery of catalase were investigated. The size of the 3D-printed microcubes was 800 nm in length of a square and 600 nm in height, which is suitable for targeting macrophages passively. Microcubes were also tunable in shape and size, and high-resolution 3D printing could provide microparticles with little variation in shape and size. Catalase was loaded on 3D-printed microcubes by nonspecific adsorption, and catalase on 3D-printed microcubes (CAT-MC) retained 83.1 ± 1.3% activity of intact catalase. CAT-MC also saved macrophages, RAW 264.7, from the cytotoxicity of H
Identifiants
pubmed: 37546651
doi: 10.1021/acsomega.3c00789
pmc: PMC10398707
doi:
Types de publication
Journal Article
Langues
eng
Pagination
26775-26781Informations de copyright
© 2023 The Authors. Published by American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Clin Biochem. 1999 Nov;32(8):595-603
pubmed: 10638941
ACS Appl Mater Interfaces. 2016 Aug 24;8(33):21107-33
pubmed: 27349465
Materials (Basel). 2018 Feb 16;11(2):
pubmed: 29462901
React Oxyg Species (Apex). 2016;1(1):9-21
pubmed: 29707643
Nat Rev Drug Discov. 2008 Jan;7(1):21-39
pubmed: 18097458
Int J Nanomedicine. 2007;2(4):595-607
pubmed: 18203427
J Control Release. 2014 Nov 28;194:1-19
pubmed: 25151983
Curr Neuropharmacol. 2009 Mar;7(1):65-74
pubmed: 19721819
Cell Physiol Biochem. 2017;44(2):532-553
pubmed: 29145191
J Drug Deliv. 2012;2012:103973
pubmed: 22645686
Nat Rev Drug Discov. 2021 Sep;20(9):689-709
pubmed: 34194012
Oxid Med Cell Longev. 2019 Nov 11;2019:9613090
pubmed: 31827713
Mater Sci Eng C Mater Biol Appl. 2017 Jan 1;70(Pt 1):842-855
pubmed: 27770962
Cells. 2019 Jul 30;8(8):
pubmed: 31366062
Drug Discov Today. 2020 Sep;25(9):1668-1681
pubmed: 32687871
Nat Rev Mater. 2021;6(12):1078-1094
pubmed: 34394960
Biotechnol J. 2010 Jan;5(1):113-28
pubmed: 20069580
Int J Mol Sci. 2019 May 15;20(10):
pubmed: 31096608
Materials (Basel). 2019 Feb 06;12(3):
pubmed: 30736388
Int J Pharm. 2019 Apr 20;561:244-264
pubmed: 30851391
Int J Pharm. 2016 Dec 30;515(1-2):300-306
pubmed: 27756626
AAPS PharmSciTech. 2021 Jan 17;22(1):49
pubmed: 33458797
Polymers (Basel). 2020 Mar 05;12(3):
pubmed: 32150904
Int J Pharm. 2018 Jun 15;544(2):415-424
pubmed: 29355656
Int J Pharm. 2013 Sep 15;454(1):388-93
pubmed: 23876501
Polymers (Basel). 2021 May 06;13(9):
pubmed: 34066639
Cent Eur J Public Health. 1996;4 Suppl:11-4
pubmed: 9167049